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The past three decades have seen liver transplantation becoming
a major therapeutic approach in the management of end-stage
liver diseases. This is due to the dramatic improvement in sur-
vival after liver transplantation as a consequence of the improve-
ment of surgical and anaesthetic techniques, of post-transplant
medico-surgical management and of prevention of disease
recurrence and other post-transplant complications. Improved
use of post-transplant immunosuppression to prevent acute
and chronic rejection is a major factor in these improved results.
The liver has been shown to be more tolerogenic than other
organs, and matching of donor and recipients is mainly limited
to ABO blood group compatibility. However, long-term immuno-
suppression is required to avoid severe acute and chronic rejec-
tion and graft loss. With the current immunosuppression
protocols, the risk of acute rejection requiring additional therapy
is 10–40% and the risk of chronic rejection is below 5%. However,
the development of histological lesions in the graft in long-term
survivors suggest atypical forms of graft rejection may develop as
a consequence of under-immunosuppression. The backbone of
immunosuppression remains calcineurin inhibitors (CNI) mostly
in association with steroids in the short-term and mycophenolate
mofetil or mTOR inhibitors (everolimus). The occurrence of
post-transplant complications related to the immunosuppressive
therapy has led to the development of new protocols aimed at
protecting renal function and preventing the development of de
novo cancer and of dysmetabolic syndrome. However, there is
no new class of immunosuppressive drugs in the pipeline able
to replace current protocols in the near future. The aim of a full
immune tolerance of the graft is rarely achieved since only 20%Journal of Hepatology 20
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ineurin inhibitors; MMF, mycophenolate mofetil.of selected patients can be weaned successfully off immunosup-
pression. In the future, immunosuppression will probably be
more case oriented aiming to protect the graft from rejection
and at reducing the risk of disease recurrence and complications
related to immunosuppressive therapy. Such approaches will
include strategies aiming to promote stable long-term immuno-
logical tolerance of the liver graft.
 2015 European Association for the Study of the Liver. Published
by Elsevier B.V.
Introduction
In the early era of liver transplantation, it was felt that rejection
was less problematic than in other organ transplantation.
Experimental and clinical studies suggested that the liver was
less sensitive to rejection than the skin, heart, lungs or kidney,
a consequence of the liver’s tolerogenic potential. This was based
on a large body of observational and experimental evidence. For
instance in pigs and some rat strains, liver transplants are
accepted without the need for immunosuppressive drugs and
furthermore the liver may induce tolerance for other trans-
planted organs and decrease the risk of rejection of associated
heart or kidney transplants [1]. Clinically hyperacute rejection
of liver transplants is an extremely rare event despite the lack
of major histocompatibility complex (MHC) matching and suc-
cessful grafts are possible across ABO blood groups and in the
presence of positive cross matches between donor and recipient
which is not true of other organ transplants [2].
During the early years of liver transplantation, serious surgical
and infectious complications dominated the post-operative per-
iod although it rapidly became apparent that although rejection
is usually less severe in liver compared with other organ trans-
plants it is still a major issue requiring immunosuppressive ther-
apy that is life-long in most patients [3–6]. Thus, before the
advent of cyclosporine, the rate of acute rejection at post-trans-
plantation day 5–7 was around 80% and although, as stated
above, liver transplants can survive in the face of ABO incompati-
bility or positive cross matches, these situations were associated
with a risk of severe life threatening acute rejection mixing cellu-
lar and humoral rejection [2]. Thus in order to achieve high long-
term graft survival rates, rejection should be efﬁciently prevented
and treated. In this review we will discuss the evolution of
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immunosuppressive protocols, their current objective, the
mechanisms of acute and chronic rejection, the basis of tolerance
and the possibility to achieve tolerance in clinical practice.
Immunosuppression in liver transplantation: evolution of
protocols
Immunosuppressive drugs used in liver transplantation
Corticosteroids
Steroids have always been used in liver transplantation. They are
administered to prevent acute rejection and commonly started
per-operatively, and given as high bolus doses to treat acute
rejection. Their widespread use in transplantation reﬂects their
many potent actions but this also leads to severe toxicity and
numerous side effects such as diabetes, infection, hypertension,
Cushing’s syndrome, poor wound healing, osteoporosis and accel-
erated cardiovascular disease. This has promoted clinicians to try
to minimize their use and with the knowledge of liver trans-
plantation evolving, the way steroids are being used has changed.
Firstly, the cumulative dose of steroids given during the ﬁrst
weeks has been drastically reduced. Many patients still receive
a loading dose initially of 500 mg, but then the dose of steroids
is rapidly tapered. In addition, in many centres steroids are dis-
continued after a few weeks or months except in some particular
cases, such as patients transplanted for autoimmune diseases,
although even here there is evidence that in many cases steroid
withdrawal is safe [7]. Therefore in many centres, patients are
free of steroids after the ﬁrst 6 months and some centres have
advocated steroid free regimes. In most centres corticosteroids
continue to be the ﬁrst line treatment for acute rejection
although the total amount of steroids given as treatment of rejec-
tion is much less than in the early years of liver transplantation.
This reﬂects the increasing realization that a lymphocytic inﬁl-
trate on liver biopsy in the ﬁrst 10 days after transplantation does
not always result in clinical rejection and that patients should
only be treated if they have biochemical evidence of graft dys-
function. Furthermore, it is now appreciated that whereas the
effect of steroids is impressive for early acute rejection it is much
less so in cases of persistent late acute rejection and chronic
rejection [8]. Thus clinicians have realized the importance of
assessing the inﬂammatory activity of rejection more carefully
by not continuing to treat with high-dose steroids once the con-
dition has evolved into the chronic phase, which is much less
responsive to steroids. Interestingly this change in practice has
been associated with a dramatic fall in the incidence of chronic
rejection so that it is now a relatively rare event in liver trans-
plantation, leading to the need for re-transplantation in less than
5% of patients [9,10]. Steroids have a Dr Jekyll and Mister Hyde
character: as an example in hepatitis C patients, steroids increase
the serum viral load and boluses of steroids increase ﬁbrosis pro-
gression but in contrast, the rapid discontinuation of steroids
after transplantation has been associated with an immune
rebound deleterious for the graft. Moreover, steroid free proto-
cols do not lead to reduced graft ﬁbrosis at 2 years probably
due to the fact that the lack of steroids was compensated for by
more aggressive immunosuppression using other agents [11].
Purine inhibitors
Azathioprine. In the very early years of liver transplantation
azathioprine and corticosteroids were the mainstay of
immunosuppression before the discovery of cyclosporine
[4–6,12]. Long-term survivors from those programmes show
the efﬁcacy of azathioprine. This is particularly demonstrated in
renal transplantation where some units switched to calcineurin
inhibitors (CNI) relatively late because of the risks of renal toxic-
ity, and despite this, have large cohorts of long-term survivors on
azathioprine-based non-CNI protocols. Since the 1980s and early
1990s azathioprine has been used in combination with steroids
and CNIs to prevent the development of rejection. Azathioprine
has never been used to treat acute rejection. Over the past
20 years the use of azathioprine has progressively reduced and
been replaced by the newer purine inhibitor mycophenolate
[13,14].
Mycophenolic acid (MPA) prodrugs
Mycophenolate mofetil (MMF). MMF is a more potent immuno-
suppressive agent than azathioprine, although one can argue that
azathioprine’s relatively weaker effect makes it a safer drug to use
in combination with CNIs. MMF is undoubtedly associated with a
reduced risk of marrow suppression and squamous cell carcinoma
of the skin but the fact that azathioprine is safe during pregnancy
whereas MMF is teratogenic in animals is in azathioprine’s favour
in women of child bearing age. The group at the Royal Free
Hospital have proposed the use of azathioprine in patients with
hepatitis C virus (HCV) infection claiming it is associated with a
slower progression of graft ﬁbrosis [15]. However, the consensus
of opinion from other studies and particularly from renal
transplantation is that azathioprine is less effective than MMF
and it is much less widely used than previously. MMF is a prodrug
of mycophenolic acid (MPA) and an inhibitor of inosine-50-
monophosphate dehydrogenase (IMPDH) an enzyme used in the
de novo synthesis of guanosine nucleotides necessary for
lymphocyte activation. Another prodrug of MPA enteric-coated
mycophenolate sodium, is also used as an immunosuppressant.
Their main side effects are leukopenia and the occurrence of
abdominal pain and particularly diarrhoea, which affects about
20% of patients but often resolves on reducing the dose. These
mycophenolate acid prodrugs are now widely used in trans-
plantation mainly in association with CNI. Like azathioprine they
are not potent enough or rapidly acting to allow them to be used
to treat acute rejection and the evidence suggests that in most
cases they are not potent enough to be used as a sole immunosup-
pressant. However, in combinationwith CNIs they allow immuno-
suppression to be maintained while minimizing the dose of CNI
and thus reduce the risk of CNI-induced renal toxicity [13,14].
Calcineurine inhibitors
Cyclosporine. Most people considered that the advent of cyclos-
porine was a therapeutic breakthrough, a true revolution that
led directly to the improved survival after liver transplantation
from its introduction in 1984 [4,5,16]. In fact this is only partially
true. Cyclosporine by its potent immunosuppressive effect
decreased both the incidence and severity of acute rejection
and was thus a major cause of improvement in the results of liver
transplantation. However the advent of cyclosporine coincided
with unprecedented improvements in the surgical, anesthesio-
logical, and medical management of liver transplantation and
these may have contributed as much if not more than the intro-
duction of cyclosporine to the extraordinary development of liver
transplantation [3–5,17]. Cyclosporine became the basis of
modern immunosuppression in combination with steroids or inJournal of Hepatology 2015 vol. 62 j S170–S185 S171
earlier years in combination with corticosteroids and azathio-
prine. Cyclosporine is able to prevent the occurrence of acute
rejection but is not effective in its treatment. The cyclosporine-
based immunosuppression protocols used in the early 1990s gave
a rate of acute rejection of 30–40% and a rate of chronic rejection
of 10–15% allowing a reduction of the use of high doses of
steroids and therefore a reduction in infectious complications
and steroid related complications. A drawback of cyclosporine A
was its low bioavailability, due to its lipophilic structure, and a
high incidence of side effects particularly the serious
complications of arterial hypertension and nephrotoxicity but
also hirsutism and gum hypertrophy which, although not life
threatening, are unacceptable to some patients. In the early
1990s cyclosporine was replaced by cyclosporine microemulsion,
which was more stable, with a signiﬁcantly better bioavailability
[18]. C2 serum level (cyclosporine blood level 2 h after ingestion
of cyclosporine microemulsion) was shown to be a better
monitoring of cyclosporine activity than through blood level of
cyclosporine [18].
Tacrolimus. Tacrolimus is a macrolide with strong immunosup-
pressive activity based on a property it shares with cyclosporine
calcineurin inhibition, despite their very different chemical struc-
ture. It was added to the armentarium of immunosuppression in
the early 1990s, ten years after cyclosporine and was initially
developed for liver transplantation [19,20]. The immunosuppres-
sive potency of oral tacrolimus is greater than cyclosporine and
its bioavailability is excellent, it has become the main CNI used
in most immunosuppressive protocols often in combination with
corticosteroids [21]. Following the introduction of these protocols
of immunosuppression, the rate of acute rejection fell progres-
sively to 20% and the rate of chronic rejection to 5% and most
cases of acute rejection are now controlled either by an increase
of tacrolimus or by boluses of steroids with a reduced total
immunosuppressive load and consequent reduction in infectious
complications. Although tacrolimus is effective in the treatment
and prevention of rejection it has side effects, particularly those
it shares with cyclosporine as a consequence of calcineurin inhi-
bition, arterial hypertension, renal toxicity and diabetes [10].
Monoclonal antibodies
Anti-IL-2 receptor antibody. Monoclonal antibodies that block the
IL-2 receptor and thereby prevent IL-2 dependent expansion of
effector T cells have been shown to prevent the development of
graft rejection in organ transplantation including liver trans-
plantation. Two products have been licensed: basiliximab, a chi-
meric antibody, and daclizumab, a humanized antibody that has
since been removed from the market. Both antibodies target
the alpha chain of the IL-2 receptor and prevents the expansion
of activated lymphocytes in the initial cascade of acute rejection.
For this reason, they should be given during the ﬁrst hours post-
transplantation and are usually administered until day 5. They
are not effective against established acute rejection and because
the IL-2 receptor is expressed at high levels on regulatory T cells
they could in theory disrupt established tolerance. They are non-
nephrotoxic leading to their use particularly after transplantation
in patients with renal failure and in protocols with delayed intro-
duction of CNI to decrease the rate of renal failure [22].
OKT3. This antibody targets the T cell receptor and is extremely
potent. It works in the context of transplantation by inducing
the apoptosis of activated T cells but unfortunately is non-speciﬁc
also destroying memory T cells involved in protection against
viral infections and immune surveillance leading to a high inci-
dence of opportunistic infections and an increased risk of lym-
phomas, which has led to its withdrawal from clinical use [23,24].
Anti-thymocyte globulin or anti-lymphocytic serum. This polyclonal
antibody from rabbit or horse origin is effective in prevention and
treatment of rejection. Due to severe complications such as lym-
phoma or opportunistic infections, the duration of administration
and therefore the overall amount administered has been reduced.
It is now administered over a maximum of 3–7 days. It is
non-nephrotoxic and therefore can be used in patients with renal
failure. It also has a place in patients with positive cross matches,
ABO incompatible liver transplantation and patients with high
risk of rejection [10].
mTOR inhibitors
Two mTOR inhibitors have been used in liver transplantation:
rapamycin (sirolimus) is licensed in kidney transplantation but
not in liver transplantation due to concerns about vascular
thrombosis in the post-operative period in early trials [25].
Although these vascular complications have not been conﬁrmed
in later trials rapamycin is not used routinely in liver trans-
plantation. Everolimus, another mTOR inhibitor, has recently been
licensed for the prevention of rejection in liver transplantation, in
speciﬁc indications it is started 1 month after the initial operation
due to its effects on wound healing [26,27]. mTOR inhibitors have
major immunosuppressive activity through their intracellular
binding to FKBP12 and inhibition of mTORC1 which blocks cell
cycle progression and IL-2 signalling in T cells. Thus they allow
T cell activation but prevent cells from proliferating in response
to IL-2. mTOR inhibitors are strong immunosuppressant’s with
low nephrotoxic effects. Their efﬁcacy is enhanced with CNI,
but they may increase the nephrotoxicity of CNI and the
combination should be used with caution using a lower dose of
CNI and careful monitoring. Although usually well-tolerated,
mTOR inhibitors have many side effects such as hypercholes-
terolemia, delayed wound healing, thrombocytopenia, mouth
ulcers and leg oedema. In addition, some cases of severe intersti-
tial pneumonia have been reported. mTOR inhibitors are interest-
ing because in addition to their immunosuppressive properties
they may promote immune tolerance (see later) and also have
anti-proliferative and anticancer properties. It has been shown
in kidney transplantation that the introduction of rapamycin
reduced the risk of skin cancer recurrence in renal transplant
patients. By extension, many authors are supporting the use of
mTOR inhibitors in patients transplanted for hepatocellular carci-
noma with the aim of reducing recurrence. They are now used in
patients with CNI related nephrotoxicity and switching from CNI
based immunosuppression to everolimus has been associated
with reversibility of renal failure in some patients [25,28,29].
New immunosuppressive drugs
It is surprising and at the same time disappointing that despite
the rapid evolution of immunosuppression during the 1980s
and 1990s the last generation of immunosuppressive drugs
entered in clinical practice are the mTOR inhibitors and in 2015
CNI are still the backbone of immunosuppression. The co-stim-
ulator blocker belatacept has failed to demonstrate a beneﬁt in
liver transplantation, in contrast to kidney transplantation, and
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other immunosuppressive drugs including leﬂunomide and the
sphingosine 1 phosphate inhibitor FTY720, have not been suc-
cessfully taken up in liver transplantation.
Efalizumab, a non-depleting humanized leukocyte function
associated antigen 1 (LFA1; CD11a) speciﬁc antibody that inhibits
LFA-1 functions such as T cell antigen presenting cells (APC), is
still in evaluation for its stabilization and antigen presentation
[10].
Protocols of immunosuppression
The evolution of immunosuppression in liver transplantation is
shown in Fig. 1. The backbone of immunosuppression remains
the CNI associated with steroids. Over the years several concepts
have emerged: the overall amount of steroids given has been dra-
matically reduced. In most immunosuppression protocols, after
an initial high-dose of steroids administered peri-operatively,
the daily dose of steroids has been reduced to 20 mg pred-
nisolone during the ﬁrst weeks post-transplantation and then
rapidly tapered until full discontinuation within the ﬁrst post-
transplant months. Some centres have advocated immunosup-
pression without steroids from the start to reduce steroids
related side effects. However this policy is not used in most cen-
tres because it puts patients at an increased risk of acute rejection
requiring high-dose corticosteroid boluses, which negate any
beneﬁt of a steroid free immunosuppression protocol.
Furthermore, effective immunosuppression in the absence of
corticosteroids may require a higher dose of CNI leading to
increased CNI toxicity. Steroid free immunosuppression was
tested in patients at risk of hepatitis C recurrence based on the
theoretical hypothesis that steroid use increases viral replication
and ﬁbrogenesis. However, in a randomized protocol including a
steroid free arm, the degree of ﬁbrosis was not reduced in the
steroid free group [11].
Key Points 1
• The current rates of acute and chronic rejection 
are 10-40% and 5% respectively
• Rejection severity can be graded histologically using the
Banff classification
• The backbone of immunosuppression remains CNI
• Medium and long-term complications of
immunosuppression are a major concern and include renal, 
metabolic, cardiovascular disease and de novo cancer
• Renal function sparing regimens are in current use
including immunosuppression combining low dose CNI
with anti-IL-2-R Ab, MPA prodrugs or everolimus
• There are currently no new major immunosuppressive
drugs in clinical trials
The concept of ‘‘renal protection’’ is an important factor in
designing immunosuppression protocols. A signiﬁcant proportion
of liver transplant patients develop renal failure during follow-up
and a major cause is CNI toxicity [30]. The CNI effect is ﬁxed
during the ﬁrst post-transplant weeks and is mostly irreversible
leading to the need to reduce CNIs to a minimum. Therefore sev-
eral schemes have been proposed during the post-transplant per-
iod: a triple drug combination with CNI, steroids and MPA
prodrugs to avoid a too high dose of CNI; a delayed introduction
of CNI around day 5 with an induction with IL-2 receptor anti-
body [22,31]. In the long-term it has been proposed to further
reduce CNI administration by introducing everolimus either com-
bined with low dose CNI or alone or with MPA prodrugs [27,28].
The treatment of acute rejection remains mostly unchanged
based on an increase of immunosuppression, a switch from
cyclosporine to tacrolimus and boluses of corticosteroids accord-
ing to the severity of histological rejection and to the response to
anti-rejection therapy. Perhaps the main advance in the treat-
ment of acute rejection is the recognition that a portal inﬁltrate
in itself is not an indication to treat and that many early inﬁl-
trates resolve spontaneously without the need for increased
immunosuppression. Treatment should be conﬁned to patients
with evidence of graft injury in whom other causes have been
excluded and rejection conﬁrmed by liver biopsy. It should be
noted that apart from the advent of everolimus there is no major
change in the immunosuppression protocols over the last decade
[32].
Speciﬁc aspects of immunosuppression
Hepatitis C patients. The immunosuppressive regimen should be
potent enough to prevent acute rejection but not so excessive
that it exacerbates HCV disease progression through increasing
viral replication and the associated accelerated ﬁbrosis. Current
data have failed to show differences in the incidence or severity
of HCV recurrence using tacrolimus or cyclosporine. However,
several studies reported that cyclosporine inhibits HCV replica-
tion in a cell-based replicon model and has a favourable impact
on response to interferon therapy as compared with tacrolimus.
Cyclosporine may act as an inhibitor of cyclophilin B during
antiviral therapy. The effect of corticosteroids on the recurrence
of hepatitis C is unclear, and seems to differ according to how
they are used. Several studies have shown that the use of steroid
boluses to treat rejection episodes increases HCV viremia by 1–2
log and worsens the severity of disease recurrence resulting in
increased patient and graft loss. By contrast, the rapid and early
withdrawal of steroids after transplantation may be deleterious
and lead to rapid development of ﬁbrosis [33–35]. However,
studies of steroid free immunosuppression regimens have found
no difference in the outcome of HCV recurrence [11]. Data on the
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Fig. 1. Timeline of immunosuppression and immunosuppressive protocols.
CNI: Cyclosporine A, Tacrolimus, Cyclosporine microemulsion, Tacrolimus
released; MMF: mycophenolate mofetil; MPA: mycophenolic acid; Anti-IL-2-R:
IL-2 receptors antibodies.
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effect of other immunosuppressive agents, such as MMF, azathio-
prine, antibodies to the IL-2 receptor and mammalian target of
rapamycin inhibitors, on HCV recurrence remain controversial.
Thus the optimal immunosuppression protocol remains to be
determined.
Long-term complications of immunosuppression
With the improvement of survival after transplantation it has
become more important to improve the long-term quality of life
of transplant patients and to reduce the side effects of
immunosuppression.
Patients are exposed to several risks:
A) A dysmetabolic syndrome characterized by the occurrence
of diabetes, arterial hypertension, and obesity [36,37].
B) Cardiovascular complications, which are now the main
cause of long-term mortality.
C) An increased risk of de novo cancer. Transplant patients
have a 100 fold increased risk of skin cancers such as baso-
cellular or squamous cell carcinoma, they have also a 3–5
fold increased risk of non-skin cancers in comparison to
the general population particularly blood cancers and gas-
trointestinal tract cancer [38,39].
D) Renal complications: chronic renal failure is one of the
main causes of long-term morbidity after liver trans-
plantation. The rate of severe renal failure is estimated at
20–25% at 5 years. As said above, the main cause of chronic
renal failure is CNI toxicity and therefore, strategies to pro-
tect the kidney of liver transplant patients are essential
[30,40,41].
Immunological basis of rejection in liver transplantation
Allograft rejection
Acute rejection
Allograft rejection is graft damage arising as a consequence of an
immunological reaction to foreign antigens on the graft.
Alloantigens are potent activators of immunity although in the
context of liver transplantation and immunosuppression a
minority of patients develop clinical symptoms and it is impor-
tant to distinguish between the immune response to the graft
and clinical rejection because only the latter requires additional
immunosuppression [42]. The incidence of clinically signiﬁcant
rejection is 10–40% in most series usually within the ﬁrst month
after transplantation [43] when liver injury results in elevated
levels of bilirubin, transaminases and alkaline phosphatase [44].
The diagnosis is conﬁrmed by the characteristic histological ﬁnd-
ings of portal inﬂammation, bile duct injury and venous inﬂam-
mation often associated with centrilobular necroinﬂammation
involving hepatic venules and surrounding hepatocytes [45].
Because milder forms of rejection can be managed without addi-
tional immunosuppressive therapy it is important to deﬁne the
severity using for instance the Banff classiﬁcation [46,47]. Late
acute rejection occurring more than three months after trans-
plantation is often a consequence of inadequate immunosuppres-
sion. It is associated with a more hepatitic appearance and more
markedly elevated serum transaminases in contrast with the cho-
lestatic picture which is characteristic of portal-based acute
rejection. It is also less responsive to immunosuppression and
more likely to become chronic [8,48] Fig. 2.
Key Points 2
• MHC antigens remain the most important alloantigens 
in graft rejection
• The liver is a tolerogenic organ and its microanatomy, 
cellular composition and cytokine microenvironment 
contribute to the easier acceptance of liver versus other 
solid organ transplants
• Rejection is a T cell driven immune response that 
predominantly targets bile ducts
• Preservation and reperfusion injury can contribute to 
the breaking of tolerance and triggering of immune 
mediated injury
• Chemokines have a role in compartmentalising 
infiltrating leukocytes and the balance of local effector 
and regulatory cells recruited determines graft outcome
Chronic rejection
With advances in immunosuppressive therapy there has been a
progressive fall in the prevalence of chronic rejection, which
now accounts for <2% of cases of graft failure. In its most severe
form it is characterized by severe bile duct damage leading to bile
duct loss and an obliterative arteriopathy with rapid progression
to graft failure although more indolent forms also occur particu-
larly in cases that present more than twelve months after trans-
plantation [49]. Chronic rejection can progress to bridging
ﬁbrosis and cirrhosis [45,50].
Antibody-mediated rejection
Antibody-mediated rejection is seen in ABO incompatible trans-
plants [51] and in the presence of preformed lymphocytotoxic
antibodies [52]. Its most severe form, hyperacute rejection, is
extremely rare and characterized by widespread haemorrhage,
microvascular thrombosis and hepatocyte necrosis as a conse-
quence of preformed antibodies binding to endothelial antigens
[52–54]. It can be prevented in recipients of ABO-I grafts by the
use of anti-B cell directed immunosuppression. Antibody-medi-
ated mechanisms are suggested by the presence of C4d deposits
in graft endothelium and may be involved in both acute and
chronic rejection and associated with more severe graft dysfunc-
tion as well as a failure to respond to immunosuppression [55]. In
addition to the very rare cases of ‘‘pure’’ hyperacute or acute anti-
body-mediated rejection cases (described above), results from
recent retrospective single-centre reports suggesting that the
presence of preformed or de novo anti-human leukocyte antigen
(HLA) antibodies could also be involved in a number of additional
negative immunological outcomes. Thus, anti-HLA donor-speciﬁc
antibodies (DSA), mostly anti-HLA class II, have been associated
with; i) increased risk of rejection and liver and kidney graft loss
in simultaneous liver-kidney transplant recipients [56]; ii) with a
higher prevalence of advanced ﬁbrosis or cirrhosis in paediatric
liver transplant recipients [57]; iii) with an increased risk of
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S174 Journal of Hepatology 2015 vol. 62 j S170–S185
post-transplant HCV-induced advanced liver ﬁbrosis in adult
recipients [58]; and iv) are more frequent in patients with
chronic rejection than in those with normal graft function [59].
The extent to which DSA inﬂuences liver allograft pathology is
still difﬁcult to estimate. Large prospective clinical trials will be
required to clarify their exact pathogenic role. In the meantime,
implementation of routine anti-HLA antibody monitoring or at
least biobanking of serum samples to do so retrospectively if
required, should be encouraged as a means to conﬁrm or dispute
existing associations.
Underlying mechanisms of rejection
Allorecognition and immune activation. Rejection results from
activation of immune pathways by alloantigens the most impor-
tant of which are the MHC antigens (Ags) [60]. Immune recogni-
tion of mismatched donor HLA results in both cellular and
humoral immune activation and allograft rejection. Although
antibody-mediated hyperacute rejection is very rare in liver
transplantation, DSA to donor MHC class I can drive complement
dependent and independent pathways that may contribute to
tissue damage in acute and chronic rejection [61–63]. Donor
HLA-speciﬁc antibodies are associated with portal capillary and
stromal C4d staining, indirect evidence of antibody-mediated
graft injury, and with an increased incidence of chronic rejection
of liver allografts [58]. However, the question of whether
antibodies are a cause or a consequence of rejection is unproven
and the relationship between DSA and graft damage is more
complex in the liver than in the case of other transplanted organs.
This is due to the fact that: i) markers of antibody-mediated
damage (i.e. circulating DSA and graft deposition of complement
protein C4d) are often present in the setting of typical acute
cellular rejection [63]; ii) the liver can absorb large amounts
of anti-HLA antibodies (particularly anti-class I) without under-
going detectable immunological damage; iii) the liver has a much
lower, although variable, expression of HLA class II antigens than
other allografts such as kidneys or hearts, which is not often
taken into account when considering the pathogenic role of
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Fig. 2. Mechanisms of graft rejection. (A) Damage to the graft during preservation and reperfusion activates the innate immune system including local NK and NK T cells
that secrete proinﬂammatory cytokines. Dendritic cells (DC) migrate from the graft to recipient lymphoid tissue where they activate alloreactive T cells that enter lymphoid
tissues from blood via high endothelial venules (HEV). Responding T cells proliferate, differentiate and secrete cytokines that promote activation of other effectors including
monocytes/macrophages and eosinophils. Effector cells are recruited to the graft from the blood via activated hepatic endothelium and destroy donor cells, particularly bile
duct cells and hepatocytes, by direct lysis (cytotoxic T lymphocytes and NK cells) cytokine-mediated effects or involvement of other cells including macrophages. Activated
T cells provide help for alloantibody production by B cells leading to antibody-mediated graft damage and complement deposition on graft endothelium. (B) There are two
types of allorecognition. Direct allorecognition occurs when T cells recognize intact foreign major histocompatible complex (MHC) molecules on donor antigen presenting
cells (APC). This pathway dominates in acute graft rejection. T cells also recognize donor peptide fragments processed by and presented on self-MHC molecules (indirect
allorecognition). This is important in chronic graft rejection but may have conﬂicting effects: providing T cell help for B cells leading to anti-graft antibodies but also
activating regulatory T cells that limit graft damage and promote tolerance. Liver resident cells including sinusoidal endothelial cells and hepatocytes also present antigens
but when they interact with naïve T cells the results is tolerance and in the case of endothelium a stop signal which prevents recruitment. (C) Effector cells are recruited to
the graft by sequential interactions with activated hepatic sinusoidal endothelium. A brief tethering capture phase is followed by chemokine triggering of integrin (LFA-1
and VLA-4) mediated adhesion to ICAM-1 and VCAM-1 on activated endothelium which leads to stable adhesion and arrest followed by migration on and through the
endothelial barrier into the graft, a process that involves chemokines, integrins and the atypical adhesion receptor vascular adhesion protein-1 (VAP-1) which has also been
implicated in sialic acid dependent tethering.
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anti-HLA class II DSA; iv) intrahepatic C4d staining has a low
speciﬁcity as a marker of antibody-mediated rejection; and v)
in contrast to other allografts, identiﬁcation of intrahepatic NK
cells or NK-derived transcripts does not seem to be associated
with antibody-mediated rejection [64–66]. Clinical studies have
shown that pre-existing donor HLA class I speciﬁc antibodies or
their early appearance post-transplant are associated with subse-
quent rejection suggesting a causative role. Furthermore, rejec-
tion is associated with anti-class I speciﬁc antibodies which is
consistent with a functional role because class I antigens are
strongly expressed on bile ducts, the principle targets in liver
rejection [63]. However, not all patients with pre-existing DSA
or who develop de novo DSA develop rejection making it difﬁcult
to justify routine monitoring in the post-transplant patient.
Nonetheless, the strong evidence implicating DSA in the patho-
genesis of rejection suggests that testing for HLA-speciﬁc
antibodies at the time of acute rejection might help determine
the likelihood of chronic rejection and thereby target patients
for more aggressive immunosuppression. The use of anti-T cell
induction therapy with daclizumab or OKT3 reduces the risk of
rejection in patients who are DSA positive suggesting that early
T cell activation is important in the generation of antibody-medi-
ated rejection [63]. Therapeutic targeting of B cells is a logical
approach and pre-transplant depletion of B cells protects from
rejection in experimental models [67]. However, the most widely
available B cell therapy, rituximab, targets CD20 which is absent
from plasma cells and memory B cells that will already be primed
in patients with pre-existing DSA. The treatment of established
antibody-associated chronic rejection is more difﬁcult and may
require different immunosuppression protocols.
Basis of acute cellular rejection
Acute rejection is a T cell driven immune response to donor anti-
gens [42], which may be recognized via three pathways termed
direct, indirect and semi-direct. In the direct pathway, intact allo-
geneic MHC molecules on donor APCs are recognized by recipient
T cells without the need for processing. This is the dominant
pathway in acute rejection whereas indirect antigen pre-
sentation, in which allogeneic antigens are taken up and pro-
cessed by APCs and presented on recipient MHC, dominates in
chronic rejection and later immune responses to the graft. The
semi-direct pathway is less well understood and involves recipi-
ent APCs that express intact donor MHC molecules as a conse-
quence of fusion with donor exosomes [68]. The initial T cell
response is characterized by inﬁltration of the graft by CD4+
and CD8+ T cells but myeloid cells and innate lymphoid cells
are involved and may determine the outcome of allorecognition
[69]. The nature of the antigen presenting cell and the site of anti-
gen presentation also have a major effect on outcome. Immune
responses in the liver differ from those in other organs as a con-
sequence of its unique microanatomy and cellular composition
[70]. The liver contains several cell types capable of processing
and presenting antigen and activating lymphocytes although
these interactions frequently result in tolerance rather than effec-
tor responses. Tolerogenic donor dendritic cells (DCs) within the
graft donor migrate into donor lymphoid tissues after trans-
plantation where they may persist and maintain tolerance.
However, graft injury or damage or the presence of infection
can activate both donor and recipient DCs to drive effector
responses explaining how preservation injury, for example, can
be associated with more severe rejection [71].
Cross presentation of antigens by hepatic sinusoidal cells usu-
ally leads to a failure of CD8 T cells to develop full effector func-
tion and this may contribute to tolerance as well as interactions
between recipient T cells and donor hepatocytes [72].
Consequently under many circumstances the outcome of T cell
activation in the liver is tolerance [73]. However, strong effector
responses can be generated under the correct conditions as
demonstrated by the strong immune response to hepatitis A virus
for example. The outcome depends in part on the site of immune
activation with activation by DCs in draining lymph nodes usu-
ally leading to a vigorous immune response whereas local activa-
tion by sinusoidal endothelial cells or hepatocytes leads to
tolerance [74,75].
The inﬂammatory microenvironment in the liver allograft affects
the outcome of allorecognition. The activation of CD4 T cells by
alloantigens is strongly inﬂuenced by the cytokine environment
in which activation takes place and this contributes to the bal-
ance between rejection and tolerance of the allograft. CD4 T cells
can differentiate into effector or regulatory phenotypes depend-
ing on the cytokines present during activation. In the presence
of IL-12, CD4+ cells become T helper 1 (Th1) cells which secrete
interferon gamma and contribute to tissue destruction.
Whereas the presence of retinoic acid and TGFb leads to the
induction of the transcription factor Foxp3 and formation of reg-
ulatory T cells (Tregs) and the combination of IL-6 with TGFb
leads to the development of IL-17 producing T cells (Th17) rather
than Tregs. The presence of IL-4 and relative lack of IL-12 drives
differentiation into T helper 2 (Th2) cells which produce IL-4, IL-
5, and IL-13 [76]. Th1 cell differentiation in response to high
intragraft levels of IFNc is an important driver of rejection [77]
although interferon is also required for the development of toler-
ance in liver transplantation [78]. Recent studies implicate Th17
cells in liver allograft rejection in both experimental models and
clinical transplantation and the balance between Th17 cells and
Tregs may be particularly important in determining outcome
[79,80].
Recruitment of effector cells to the rejecting allograft. Hepatic
inﬂammation as a result of allorecognition leads to activation of
resident immune cells and the recruitment of leucocytes from
the circulation mediated by combinations of adhesion molecules
and chemotactic cytokines that drive transendothelial migration
into liver tissue [81]. In the case of the liver, direct visualization
of leucocyte recruitment using intravital microscopy has shown
that leucocytes are capable of adhesion and migration across dif-
ferent regions of the hepatic microvasculature but the majority of
leukocyte migration occurs across the hepatic sinusoids [82]. The
hepatic sinusoidal endothelium has a unique structure and phe-
notype and this together with the relatively low levels of shear
stress in the sinusoids has led to the involvement of distinct
combinations of receptors including vascular adhesion protein-
1 (VAP-1), which has been demonstrated to mediate lymphocyte
recruitment to the liver during graft rejection [83].
Activation of graft endothelium by injury or local inﬂamma-
tion leads to increased adhesion molecule expression and chemo-
kine secretion leading to increased inﬁltration of lymphocytes
into the graft. Chemokines are critical for leucocyte recruitment
and the gamma interferon inducible chemokines CXCL9 and
CXCL10 are induced during liver allograft rejection and recruit
effector cells expressing their cognate receptor CXCR3 [84].
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Furthermore this axis is activated early during preservation
reperfusion injury and may be critical for initiating the effector
response during allograft rejection [85].
Chemokines also have an important role for the compartmen-
talization of inﬁltrating leukocytes during liver allograft rejection.
Cholangiocytes, the primary targets of acute cellular rejection,
secrete several chemokines including not only CXCL9 and
CXCL10 but also CCL20 which selectively recruits IL-17 secreting
Th17 and Tc17 cells to the bile ducts which may be an important
step in targeting immune damage at intrahepatic bile ducts dur-
ing rejection [86]. Thus the microenvironment of the liver graft is
critical in determining the outcome of allorecognition and this
will be affected by many factors including donor age and under-
lying conditions such as steatosis, the severity of preservation
reperfusion injury and the presence of infection all of which
affect the inﬂammatory state of the graft.
Mechanisms of hepatocyte and bile duct destruction in rejection
In graft rejection cytotoxic T cells and other effector leukocytes
bind to bile ducts and hepatocytes, which they then kill, using
several molecular mechanisms. Cytolytic T cells can kill targets
through the granzyme/perforin pathway, which is activated fol-
lowing engagement of the CD8 T cell receptor/MHC complex.
However, hepatocytes are relatively resistant to this type of kill-
ing and the dominant mechanism of both hepatocyte and cholan-
giocyte killing involves members of the TNF superfamily [87].
During liver inﬂammation, including allograft rejection, the TNF
superfamily receptors CD40, TNFR1, TNFR2, and TRAIL receptors
are increased on hepatocytes and cholangiocytes allowing CD8+
T cells, macrophages, and NK cells, which express ligands for
these receptors to participate in liver cell killing [88,89]. In addi-
tion cholangiocytes are susceptible to replicative senescence. This
results from ischemia and oxidative stress during graft preserva-
tion and reperfusion injury, which sensitizes them to subsequent
immune-mediated injury during rejection [90,91]. An important
factor in irreversible bile duct loss is the microvasculature that
supplies the intrahepatic biliary tree. The microvasculature itself
is a target of the alloresponse in rejection and can thus be
destroyed as part of the rejection process. Even severe damage
to bile ducts is reversible as long as the microvasculature is pre-
served but once this is lost irreversible bile duct loss ensues [92].
Together, these pathways drive cholangiocyte destruction, ductu-
lar reaction and periportal ﬁbrosis culminating in the vanishing
bile duct syndrome that is characteristic of chronic rejection.
The clinical consequence is progressive jaundice, liver failure
and in some circumstances the development of graft cirrhosis.
Clinical aspects
Acute rejection
In clinical practice, acute rejection occurs around day 5 post-
transplantation. However, evidence of a lymphocytic inﬁltrate
of portal tracts can be present histologically as early as day one
but such inﬁltrates may not represent rejection and may in fact
be part of graft recognition leading to eventual immune toler-
ance. Currently it is considered that histological features of rejec-
tion without any biological consequences should not be treated
and for this reason, routine protocol biopsies are no longer car-
ried out in most centres. In contrast, any clinical suspicion of
acute rejection needs to be conﬁrmed histologically to assess
histological severity and to exclude other causes (drug toxicity,
ischemic hepatitis, infection, recurrent disease) before treatment
is started. Acute rejection usually has few clinical symptoms and
the diagnosis is based on increases of liver enzymes ALT, AST,
GGT and alkaline phosphatase. The increase in INR is usually
minimal or mild. Ultrasound doppler of the liver shows an
absence of dilation of intrahepatic biliary tree, and patent hepatic
artery and portal vein. In severe forms of rejection, the portal ﬂow
can be slow due to an increase in vascular resistance through the
inﬂamed liver, and portal oedema may be detected on CT
scanning.
Histologically acute rejection is now classiﬁed according to
the Banff criteria (Table 1), which classify the grade of inﬂamma-
tory inﬁltrate in the portal space, around biliary ducts, and in ves-
sel walls. The decision to treat acute rejection is based on the
severity of biochemical abnormalities and the Banff criteria.
Fine needle biopsies are no longer used for the diagnosis of acute
rejection. Minimal and mild acute rejection can be treated with
an increase of immunosuppression dosing. Severe acute rejection
usually requires boluses of high-dose steroids.
Hyperacute rejection or humoral rejection
In ABO incompatible transplants or those done in the presence of
a positive cross match, a particular form of rejection with features
of hyperacute or humoral rejection can be seen. This event is not
immediate and is usually delayed for a few days occurring at any
time during the ﬁrst ten days. Clinically, it can be extremely sev-
ere with dramatic increase of AST and ALT and increase in INR
associated with acute liver failure and progression to multiple
organ failure. The liver is engorged with areas of haemorrhagic
necrosis. Histologically there is a marked portal inﬁltrate with
haemorrhagic lobular necrosis and endothelial damage [93]. In
Table 1. Histological features of acute rejection according to Banff criteria and calculation of rejection activity index.
Category Criteria Score
Portal inflammation Lymphocytic infiltration in few triads
Mixed infiltrate in most triads
Marked expansion of all triads by a mixed infiltrate
1
2
3
Bile duct inflammation and damage Minority of ducts infiltrated by inflammatory cells
Most of the ducts infiltrated by inflammatory cells with degeneration
As above to 2, most ducts showed degenerative changes
1
2
3
Venous endothelial inflammation Subendothelial lymphocytic infiltrate in a minority of portal/hepatic venules
Subendothelial lymphocytic infiltrate in most of portal/hepatic venules
As above for 2 with moderate or severe inflammation with perivenular necrosis
1
2
3
Total score: some of the components.
Score 1–3 minimal rejection; 4–6 mild rejection; 7–9 severe rejection.
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the 1990s, ABO incompatible liver transplantation was performed
for some emergency cases but was associated with a high inci-
dence of not only humoral rejection but also a particular form
of chronic graft dysfunction characterized by progressive
destructive cholangitis leading to graft failure [51,54]. More
recently, ABO incompatible transplantations have been
attempted again particularly in living donor transplantation ini-
tially in transplantation for children, then for adults. With living
donation transplantation it is possible to prepare the recipient
using plasmapheresis of immunoabsorption to deplete antibodies
and prevent B cell activation and thus reduce the risk of
hyperacute and humoral rejection [94].
Chronic rejection
End-stage chronic rejection is characterized by immune destruc-
tion of bile ducts leading to a cholestatic state. The diagnosis is sus-
pected clinically by the exclusion of other causes of cholestasis:
biliary obstruction, recurrent cholestatic hepatitis C. Usually
chronic rejection is preceeded by episodes of acute uncontrolled
rejection. However this is not always the case. Histologically
chronic rejection is characterized by destruction of interlobular
bile ducts (vanishing bile duct syndrome) associated with
cholestasis. It is frequently associated with centrilobular inﬂam-
mation and necrosis and with foam cell lesion within intrahepatic
arterial branches. The different types of chronic rejection and
histological deﬁnitions have been classiﬁed according to Banff cri-
teria (Table 2). The prevalence of chronic rejection is around5–15%
according to deﬁnitions. Fortunately in liver transplantation,
chronic rejection leading to re-transplantation is relatively rare
(5%). However chronic rejection is probably underestimated due
to the absence of liver biopsies performed routinely on the long-
term inmost centres and because other long-term graft pathology
may represent atypical forms of chronic rejection e.g. graft hepati-
tis and even graft ﬁbrosis and cirrhosis of unknown cause [95,96].
Centres in which routine liver biopsies are performed have shown
that histological signs of chronic rejection can be present and fre-
quently worsen with time [95,96].
Atypical forms of rejection
De novo allo- or auto-immune hepatitis on the graft
Clinically it is characterized by an increase in AST and ALT with
histological features of autoimmune hepatitis associate in some
cases with the emergence of autoantibodies and of elevated
immunoglobulin G levels. This hepatitis is frequently sensitive
to reintroduction or increase of steroidal use [97–99].
Idiopathic post-transplant hepatitis (IPTH)
This form of hepatitis of unexplained cause has been described by
centres performing routine liver biopsies. In most cases patients
also have low level transaminases suggesting that long-term
patients should be biopsied if they have persistently abnormal
liver function tests. In some cases IPTH can progress to ﬁbrosis
and even cirrhosis. The effect of steroids on IPTH is controversial.
It is unclear if IPTH is an atypical form of chronic rejection
[95,100].
Long-term graft biopsies
Centres who performed routine long-term liver biopsies have
shown the presence of histological lesions in some patients
who have persistently normal liver enzymes. In some patients
these lesions may evolve over time with the development of
histological features such as ductopenia, IPTH, alloimmune hep-
atitis, venoocclusive disease [101], suggesting the occurrence of
subclinical atypical rejection raising the issue of the need for
long-term immunosuppression (see later) [95,96,100].
Tolerance in liver transplantation
Mechanisms and basic aspects
The liver exhibits a unique immunologic microenvironment and
responds differently to rejection and immune-mediated injuries
compared to other organs. The two most well-known mani-
festations of this process are: 1) that antigen presentation within
the liver, which is mediated by a variety of cell types such as
dendritic cells, Kupffer cells, sinusoidal endothelial cells, and
hepatocytes, leads to tolerization of T cells rather than T cell–
mediated immunity; and 2) that pattern recognition receptors
such as Toll-like receptors (TLRs) expressed by liver cells often
respond differently to pathogen associated molecular patterns
than what is observed in other tissues (e.g. lipopolysaccharides
exerts immunosuppressive effects in the liver, while it behaves
as a potent immunostimulatory molecule elsewhere). This
environment has evolved to support the key immune surveillance
functions exerted by the liver, which is responsible for clearing
Table 2. Histological features of early and late chronic liver allograft rejection, adapted from Demetris et al. Hepatology 2000; 31: 792–799.
Structure Early CR Late CR
Small bile ducts Degenerative changes
Involving a majority of ducts
Bile duct loss <50%
Degenerative changes
Loss in ≥50% of portal tracts
Inflammation
Zone 3 necrosis and inflammation
Focal obliteration
Bridging fibrosis
Loss <25% of portal tracts Loss >25% of portal tracts
Terminal hepatic venules and zone 3 
hepatocytes
Portal tract hepatic arterioles
Other Spotty hepatocyte necrosis Sinusoidal foam cell accumulation
Marked cholestasis
Large perihilar hepatic artery Intimal inflammation
Focal cell deposit without lumen cell compromise
Luminal narrowed by subintimal foam cells
Large perihilar bile ducts Inflammation damage
Focal cell deposition
Mural fibrosis
CR, chronic rejection.
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blood-borne pathogens without eliciting undesirable destructive
immune responses against food-derived antigens and intestinal
bacterial degradation products delivered by the portal venous
ﬂow. In spite of the default bias towards immunoregulation and
tolerance, the liver can promote powerful effector immune
responses when exposed to live pathogens, large quantities of
danger-associated molecular patters, or in the presence of dys-
functional immunoinhibitory pathways (i.e. autoimmunity). The
mechanisms ultimately responsible for the switch from tolerance
to effector immunity are not entirely understood and are likely
the result of a complex interplay between immune and non-im-
mune liver cells [102,103,82] Fig. 3.
Key Points 3
• Immunosuppression weaning can be achieved in 20% 
of selected transplant patients
• HCV eradication is recommended before attempting 
immunosuppression weaning in HCV recipients
• The role of anti-HLA DSA in liver graft rejection is still
partly unknown in contrast to other organs and requires
further studies
• Infusion of ex-vivo expanded donor-specific suppressor 
T cells to induce tolerance is in investigation
• MSC infusions to induce tolerance is in investigation
• Machine organ perfusion may reduce immunogenicity 
and play a role in immunosuppression management
• Conventional immunosuppressive drugs will probably remain
the backbone of future immunosuppression, but an
“à la carte” immunosuppression strategy is mandatory
The liver’s unique environment is distinctly apparent in the
setting of liver transplantation, in which it is responsible for
the spontaneous acceptance of liver allografts observed in many
animal models [104,105]. This was ﬁrst demonstrated in pigs,
and subsequently in rats (in which spontaneous tolerance or
rejection occur depending on the donor-recipient strain combina-
tion) and in mice. Animals spontaneously accepting MHC-mis-
matched liver allografts develop donor-speciﬁc tolerance, which
allows them to accept skin grafts from the same donor without
the need for therapeutic immunosuppression. Rodent models of
spontaneous liver allograft tolerance have been particularly use-
ful in providing mechanistic information. A key aspect of the
development of spontaneous liver allograft tolerance is the obser-
vation that, shortly after transplantation, recipient lymphocytes
inﬁltrate the transplanted liver and accumulate in the portal
and central areas. Liver-inﬁltrating lymphocytes become acti-
vated and induce a mild degree of parenchymal damage with
increased serum aminotransferases, but instead of destroying
the graft they are gradually cleared from the liver by a phe-
nomenon that likely involves lymphocyte apoptosis and/or T cell
degradation within hepatocyte lysosomes (suicidal emperipole-
sis) [75,106–109]. At least in the mouse model this process is
dependent on CD4+CD25+Foxp3+ regulatory T cells, as depletion
of this lymphocyte subset using an anti-CD25 antibody before
transplantation prevents the tolerance development and results
in alloimmune graft destruction [110]. However, spontaneous
liver transplant tolerance in other models cannot be transferred
by Tregs in the ﬁrst few weeks following transplantation imply-
ing that Tregs alone cannot always induce tolerance [111].
Tolerance and weaning of immunosuppression
The outcome following clinical liver transplantation clearly
differs from what is observed in animal models, in that graft
rejection rapidly occurs unless patients receive strong pharmaco-
logical immunosuppression. As compared with other clinical
transplantation settings, however, it is clear that human liver
allografts also display unique immunological features. Thus, liver
transplantation can be performed across a positive cross match,
requires less vigorous immunosuppressive regimens, does not
signiﬁcantly beneﬁt from HLA matching, and is associated with
less frequent chronic rejection. While some of these characteris-
tics can be attributed to the unmatched regenerative capacity of
liver grafts, liver transplantation is the only setting in which a
signiﬁcant proportion of patients can eventually discontinue
maintenance immunosuppression without undergoing rejection,
a phenomenon known as spontaneous operational tolerance.
The observation that liver transplant recipients can occasionally
maintain stable graft function for a long period of time in the
absence of immunosuppressive medication was originally
reported in the early 1990s in Pittsburgh [112–114]. Following
these original reports, several single centres described their
experiences with the discontinuation of immunosuppression
due to patient non-compliance, in the setting of cancer or severe
infections, or performed intentionally under medical supervision
[115–122]. Taken together, these observations suggested that
approximately 20% of selected liver recipients could safely
discontinue their maintenance immunosuppression [123]. More
recent data derived from multi-centre immunosuppression
withdrawal trials, have contributed to clarify the prevalence
and natural history of spontaneous operational tolerance. A US
multi-centre paediatric trial enrolled 20 recipients of parental liv-
ing donor liver grafts at least 4 years after transplantation [124].
Drug withdrawal was successful in 12 patients, who have now
been off immunosuppression for more than 6 years. Successful
drug withdrawal was deﬁned as 1 year off immunosuppression
with normal liver function tests. Protocol liver biopsies, per-
formed at enrollment, and 2 and 4 years after complete drug dis-
continuation, did not show clinically signiﬁcant histological
changes. The only clinical parameter correlating with successful
drug withdrawal was time since transplantation. A European
multi-centre adult trial enrolled 102 recipients of cadaveric liver
grafts, out of whom 41 reached the primary endpoint, deﬁned as
stable biochemical and histological graft status for 1 year after
complete drug discontinuation [125]. Liver biopsies were
obtained at baseline and 1 and 3 years post-withdrawal.
Operationally tolerant patients have now been off drugs for more
than 5 years, and reinstitution of immunosuppression has not
been required in any case. At enrollment, and as compared with
patients who rejected, operationally tolerant recipients had an
increased time after transplant, were older and predominantly
male. The effect of time was striking: only 13% of patients trans-
planted for less than 6 years successfully withdrew their
immunosuppression, while this occurred in 79% of recipients
enrolled in the study more than 11 years after transplantation.
In liver recipients who were 6–11 years post-transplant, the
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success rate was 38%. In addition to these two trials, preliminary
data from an on-going US randomized adult trial reported in
2011, revealed that out of 18 patients in whom immunosuppres-
sion withdrawal was attempted during the second year post-
transplant, only two succeeded. This further supports the notion
that time after transplantation is a key parameter associated with
spontaneous operational tolerance. How representative of the
overall transplant recipient population are the patients enrolled
in these immunosuppression withdrawal trials remains to be
fully clariﬁed. Patients with a history of autoimmune liver disease
are typically excluded, as they are known to have a higher risk of
rejection and/or disease recurrence. In addition, HCV-negative
recipients exhibiting clinically signiﬁcant graft inﬂammation
and/or ﬁbrosis are also considered non-eligible. Among recipients
with normal liver function tests, approximately 20–30% of adult
recipients would not meet histological eligibility criteria, but this
could be 50% or more in paediatric recipients. HCV-infected
recipients can also be weaned off immunosuppression [126].
Indeed, in a recent clinical trial in which 25 liver recipients with
chronic HCV hepatitis discontinued their immunosuppression,
success was associated with immunological parameters pre-
viously known to be associated with HCV immune evasion, sug-
gesting that in some HCV-infected recipients the virus
facilitates the discontinuation of immunosuppression by mod-
ifying the liver’s immunological microenvironment [127].
Although feasible, drug withdrawal in HCV-infected recipients
is considerably more complex than in HCV-negative patients, as
early detection of rejection in the presence of abnormal liver
function tests and/or chronic hepatitis may be difﬁcult.
Consequently, eradication of HCV with direct antiviral agents is
likely to become the preferred option before considering
immunosuppression withdrawal.
A number of clinical trials are currently in progress both in
Europe and the US. These will serve to conﬁrm the high preva-
lence of tolerance among long-term surviving recipients, help
clarify the mechanisms relevant to human liver allograft toler-
ance, and determine whether it is possible to prospectively iden-
tify tolerant recipients on immunosuppression by employing
diagnostic biomarkers.
The future of immunosuppression
Immunosuppressive drugs are a double-edged sword, prolonging
the functional life of liver allografts but at the same time shorten-
ing the life of transplant recipients, as compared to the non-
transplanted general population. There is still a need therefore
for drugs with less toxicity that will be easier to adhere to.
Newer immunosuppressive drugs, particularly biological agents
such as monoclonal antibodies and fusion proteins, continue to
be tested within industry-sponsored clinical trials. Most of these
trials, however, are focused on autoimmune diseases and not in
organ transplantation. An additional limitation in the ﬁeld of liver
transplantation is the lack of well-accepted surrogate markers of
Kupffer 
cell
LPS
LSEC
Regulatory
T cell
Dendritic
cell
The liver micro-environment 
promotes the induction of 
regulatory T cells
Intra-hepatic dendritic
 cells maintain an 
immature phenotype
The liver releases soluble 
MHC molecules that can 
bind alloantibodies and/or 
inactivate alloreactive T cells 
Effector 
T cell
Hepatocytes
The intra-hepatic expression
 of MHC class II molecules
 is reduced, although this can
 increase upon inflammation 
Effector T cells are inactivated
 and/or deleted following
 intra-hepatic alloantigen recognitionHepatocytes, LSECs, 
Kupffer cells and stellate cells
can act as non-professional
antigen presenting cells
Portal blood contains LPS
and other bacterial products
 that are taken up by 
Kupffer cells and LSECs
Fig. 3. Mechanisms of liver allograft tolerance. The liver contains multiple subsets of dendritic cells, which are professional antigen presenting cells, but that tend to
maintain an immature and non-immunogenic phenotype. Kupffer cells, liver sinusoidal endothelial cells (LSEC), stellate cells and hepatocytes can also act as non-
professional antigen presenting cells, but tend to deliver suboptimal T cell priming and induce dysfunctional T cells. Continuous exposure to lipopolysaccharides (LPS) by
cells expressing Toll-like receptor-4 (TLR4), such as Kupffer cells and LSEC, results in downregulation of co-stimulatory molecules and production of immunosuppressive
cytokines. Spontaneous liver allograft tolerance requires the presence of regulatory T cells, whose generation is promoted by the liver microenvironment. The liver releases
substantial amounts of MHC molecules (particularly class I), which can exert immunomodulatory properties.
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hard clinical endpoints such as graft or patient survival, which
hampers the performance of reasonably sized clinical trials. In
this scenario, the development of novel immunosuppressive
strategies is mostly undertaken within academic investigator-dri-
ven studies. Immunomodulatory cell therapy with ex vivo
expanded regulatory T cells is currently being tested to intention-
ally induce liver transplantation tolerance early after trans-
plantation. Of these trials, the most advanced shows the
infusion of recipient ex vivo expanded donor-speciﬁc suppressor
T cells allowing for the successful discontinuation of immunosup-
pression in 6 out of 10 living donor liver transplant recipients,
although aggressive recipient conditioning with cyclophos-
phamide and splenectomy was required. [128]. The effects of
mesenchymal stromal cell (MSC) infusions are also being
explored within a variety of clinical trials, which aim at improv-
ing preservation injury, preventing ischemic cholangiopathy, or
facilitating immunosuppression minimization. While these are
very promising pilot studies, key issues related to the clinical
use of immunomodulatory cell therapy (e.g. dosing, timing, most
appropriate adjunctive immunosuppression) will need to be
clariﬁed before large scale clinical applications can be considered.
The use of machine perfusion to preserve liver allografts is likely
to inﬂuence how immunosuppressive drugs are employed as
well, given that in experimental animal models machine perfused
liver allografts exhibit substantially reduced immunogenicity
[129]. Advances in organ bioengineering and xenotransplantation
could also radically modify the management of immunosuppres-
sion following transplantation. The use of acellular liver scaffolds
repopulated with patient derived cells is far from being a fantasy,
and is likely to be tested within pilot clinical trials over the next
decade [130]. Another approach is to develop xenochimeric livers
by injecting pluripotent human stem cells into animals with
speciﬁc organogenesis defects, or into xenogeneic embryonic pri-
mordium [131]. Looking into the future, conventional immuno-
suppressive drugs will likely remain the mainstay of the
management of liver transplant recipients. The current ‘‘one size
ﬁts all’’ strategy however will certainly be superseded. Selected
recipients will require no immunosuppression at all as a result
of intentionally-induced or spontaneously developed tolerance.
In the remaining patients immunosuppression will be managed
Table 3. Overview on current and future strategies to optimize immunosuppression in clinical liver transplantation.
Objective Potential strategies Current challenges Ref.
Development of targeted 
immunosuppressive regimens
Small molecules, antibodies or fusion proteins 
directed against molecules involved in T cell 
activation, or targeting specific immune cell subsets 
(e.g., anti-CD40, anti-CD28, anti-CD20, anti-IL-12, 
anti-CD2, bortezomid)
• The relatively small patient population,
increased costs of clinical trials,
and lack of clinically relevant short-
term endpoints prevent systematic
investigation of new reagents in liver
transplantation
[132]
Development of biomarkers to 
miminize immunosuppression
Anti-HLA antibodies • Large prospective studies required to
confirm pathogenicity and the effects of
different immunosuppressive regimens
[56]
[57]
[58]
[59]
Non-invasive transcriptional and/or serological 
markers of rejection (e.g., CXCL10, CXCL9, miRNA)
• Biomarkers not yet validated in liver
transplantation
[133]
Donor specific cellular assays (e.g., ELISpot, flow 
cytometry functional assays)
• Biomarkers not yet validated in liver
transplantation
[133]
Identification of spontaneous 
operational tolerance
Use of biomarkers to select patients for drug withdrawal • Biomarker validation in independent 
larger cohorts of patients required
• Only selected recipients long time after
transplant likely to benefit
[127]
[134]
Induction of tolerance Adoptive transfer of ex vivo expanded regulatory T cells • Very high cost 
• Requires very complex infrastructure
particularly if donor-specific cells are
being generated
[128]
[135]
[136]
Adoptive transfer of mesenchymal stromal cells • Heterogenous results in experimental
animal models
• Not investigated for this indication in
clinical organ transplantation
[137]
[138]
Induction of donor-type hematopoietic chimerism • Requires aggressive recipient
conditioning
• Currently unfeasible outside of living
donor transplantation
[139]
Expansion of endogenous regulatory T cells 
(e.g., low-dose IL-2 therapy)
• Not tested in organ transplantation [140]
[141]
Modulation of the liver allograft 
immunogenicity
Use of ex vivo machine perfusion of liver allografts 
to modulate inflammatory responses
• Effects beyond the early post-transplant
period still not investigated
[129]
Generation of bioengineered 
liver grafts
Use of acellular liver scaffolds repopulated with 
patient derived cells.
• Experimental strategies not yet
investigated in relevant pre-clinical
models
[130]
[131]
[142]Development of xenochimeric liver grafts
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according to the quality of the transplanted organ, recipient co-
morbidity proﬁle, underlying graft inﬂammatory status, and
degree of cellular and/or humoral sensitization (Table 3).
Conclusion
Immunosuppression took a great part in the dramatic improve-
ment in the results of liver transplantation. The future should
concentrate on the reduction of side effects due to immunosup-
pressive drugs in the aim to improve long-term quality of life
with preservation of the long-term viability of the liver graft.
Tolerance is an achievable goal in a minority of patients.
Processes to increase tolerance of the liver allograft have to be
developed.
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